Compare Albertsons Companies Inc (ACI) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albertsons Companies Inc vs Bristol-Myers Squibb Co — how do they compare? Albertsons Companies Inc trades at $14.25 (market cap $6.93B), while Bristol-Myers Squibb Co trades at $57.67 (market cap $118.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 17.1× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| ACI | BMY | |
|---|---|---|
Market Cap | $6.93B | $118.38B |
Sector | Consumer Staples | Health |
52-Week High | $22.33 | $62.37 |
52-Week Low | $13.45 | $42.60 |
Enterprise Value | $22.02B | $154.32B |
Dividend Yield | 4.81% | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons Companies (ACI) trades at $14.14, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong earnings momentum with three consecutive quarterly beats, though profitability margins remain thin at 0.26% net income margin. Analyst consensus is bullish with a $18.75 price target representing 33% upside potential. Recent developments include AI-powered search enhancements and retail media partnerships driving innovation.
ACI presents a compelling value opportunity with attractive valuation metrics (P/S: 0.09, EV/EBITDA: 6.49) and consistent revenue growth, though investors face risks from declining profit margins, increasing debt levels, and competitive grocery market pressures. The technical picture remains bearish despite fundamental strengths.
Bristol Myers Squibb (BMY) trades at $57.97, down 0.28% today, with a bullish technical signal and consistent earnings beats. The company maintains strong profitability with a 15.01% net income margin and a 4.3% dividend yield. Recent news highlights its growth portfolio now comprising over 54% of revenues, though patent cliff concerns persist. Cash flow from operations remains robust at $14.16B for 2025, supporting dividend sustainability.
BMY offers value with a P/E of 15.88 below industry averages, but faces significant patent expiration risks that could pressure future revenues. Analyst consensus is mixed with a $64.33 price target suggesting 11% upside. The stock is a cash flow machine with upside potential if new drug pipelines deliver, though investors must weigh growth execution against legacy portfolio declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
